Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shandong Simcere Biopharmaceutical Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units, indicating that the company's current filings are being reviewed in different specialized environments. LEE, YIE CHIA is the busiest examiner, overseeing 1 pending office action. This means the 2 pending office actions are split evenly among the examiners involved. Practitioners must adapt their strategies to the specific preferences of 2 distinct examiners.
The use of 2 distinct art units within the Biotechnology & Pharmaceuticals sector suggests the technology may involve different biological or pharmaceutical categories. Because 2 distinct examiners are reviewing the work, the applicant faces a variety of perspectives on patentability. LEE, YIE CHIA is responsible for 1 pending office action, making this examiner a key figure in the company's current prosecution efforts. The presence of 2 pending office actions requires a coordinated approach to ensure consistency in technical disclosures and legal arguments. Navigating 2 distinct art units also means the company must stay current on the specific examination practices of each group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| MIDDLETON, DANAYA L | 1 | 49.5% | +48.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274845 | HUMANIZED ANTIBODY AGAINST TNFR2 AND USE THEREOF | LEE, YIE CHIA | — |
| 17925547 | HUMAN IL-15 MUTANT AND USES THEREOF | MIDDLETON, DANAYA L | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18274845 | HUMANIZED ANTIBODY AGAINST TNFR2 AND USE THEREOF | LEE, YIE CHIA | 1642 | §112 | Non-Final OA | — | Pending | Jul 28, 2023 |
| 17925547 | HUMAN IL-15 MUTANT AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §112DP | Final Rejection | — | Pending | Nov 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShandong Simcere Biopharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Yie Chia Lee has the most, with 1 of Shandong Simcere Biopharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
